Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® (SKORE)
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated With Rebif
Sponsor: Merck KGaA, Darmstadt, Germany
Listed as NCT01075880, this observational or N/A phase trial focuses on Multiple Sclerosis, Relapsing-Remitting and remains completed. Sponsored by Merck KGaA, Darmstadt, Germany, it has been updated 8 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jan 2019 — Jan 2021 [monthly]
Completed
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
- Merck spol.s.r.o., Czech Republic
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Brno, Czechia , Hradec Králové, Czechia , Motol, Czechia , Olomouc, Czechia , Ostrava, Czechia , Pardubice, Czechia , Pilsen, Czechia , Prague, Czechia , Teplice, Czechia , Zlín, Czechia and 1 more location